# Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics

> **NCT01001962** · PHASE4 · UNKNOWN · sponsor: **Aristotle University Of Thessaloniki** · enrollment: 1054 (estimated)

## Conditions studied

- Hypertension
- Type II Diabetes

## Interventions

- **DRUG:** empagliflozin
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT01001962
- **Lead sponsor:** Aristotle University Of Thessaloniki
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-01
- **Primary completion:** 2019-01
- **Final completion:** 2020-01
- **Target enrollment:** 1054 (ESTIMATED)
- **Last updated:** 2015-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01001962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01001962, "Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01001962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*